Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

Pediatrics

Volumn 119, Issue 1, 2007, Pages 11-18

  Block, Stan L ^a   Vesikari, Timo ^b   Goveia, Michelle G ^c   Rivers, Stephen B ^c   Adeyi, Ben A ^c   Dallas, Michael J ^c   Bauder, Jeffrey ^c   Boslego, John W ^c   Heaton, Penny M ^c  

^a Kentucky Pediatric Research Institute   (United States)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Efficacy; Gastroenteritis; Rotavirus; Rotavirus vaccine; Safety

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE; VIRUS ANTIBODY; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; WC3 ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; IRRITABILITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHELF LIFE; SIDE EFFECT; VACCINATION; VOMITING; ACUTE DISEASE; BLOOD; FECES; GASTROENTERITIS; HOSPITALIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; ROTAVIRUS; VIROLOGY; VIRUS INFECTION;

ACUTE DISEASE; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FECES; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN A; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 33846907238     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2058     Document Type: Article

References (24)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9:565-572
2. Ho MS, Glass RI, Pinsky PF, Anderson LJ. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis. 1988;158:1112-1116
3. Chang HG, Glass RI, Smith PF, Cicirello HG, Holman RC, Morse DL. Disease burden and risk factors for hospitalizations associated with rotavirus infection among children in New York State, 1989 through 2000. Pediatr Infect Dis J. 2003;22:808-814
4. Matson DO, Staat MA, Azimi P, Bernstein DI, Ward R, Berke T. Comparison of epidemiologic and active definitions for estimating rotavirus disease burden among hospitalized children. Presented at: annual meeting of the Infectious Disease Society of America; September 30-October 3, 2004; Boston, MA. Abstract 540
5. Hsu VP, Staat MA, Roberts N, et al. Use of active surveillance to validate International Classification of Disease code estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115:78-82
6. Vesikari T, Rautanen T, Von Bonsdorff CH. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl. 1999;88:24-30
7. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005;15:29-56
8. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis. 1996;174(suppl 1):S73-S80
9. Vesikari T, Clark HF, Offit PA, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006;24:4821-4829
10. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33
11. Centers for Disease Control and Prevention. Laboratory-based surveillance for rotavirus: United States, July 1996-June 1997. MMWR Morb Mortal Wkly Rep. 1997;46:1092-1094
12. Clark HF, Borian FE, Bell LM, Modesto K, Gouvea V, Plotkin SA. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominant serotype 1 rotavirus season. J Infect Dis. 1988;158:570-587
13. Ward RL, McNeal MM, Clemens JD, et al. Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses. J Clin Microbiol. 1991;29:449-456
14. DiStefano DJ, Kraiouchkine N, Mallette L, et al. Novel rotavirus VP7 typing assay using a one-step reverse transcriptase PCR protocol and product sequencing and utility of the assay for epidemiological studies and strain characterization, including serotype subgroup analysis. J Clin Microbiol. 2005;43:5876-5880
15. Dolan KT, Twist EM, Horton-Slight P, et al. Epidemiology of rotavirus electropherotypes determined by a simplified diagnostic technique with RNA analysis. J Clin Microbiol. 1985;21:753-758
16. Ward RL, Bernstein DI, Smith VE, et al. Rotavirus immunoglobulin A responses stimulated by each 3 doses of a quadrivalent human/bovine reassortant rotavirus vaccine. J Infect Dis. 2004;189:2290-2293
17. Clark HF, Bernstein DI, Dennehy PH, et al. Safety, efficacy, and immunogenicity of a live quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants [published correction appears in J Pediatr. 2004;144:558]. J Pediatr. 2004;144:184-190
18. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, for the US Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US Children. JAMA. 1995;273:1191-1196
19. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics. 1996;97:7-13
20. Joensuu J, Koskenniemi E, Pang X, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997;350:1205-1209
21. Velázquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis. 2000;182:1602-1609
22. González R, Franco M, Sarmiento L, Romero M, Pérez-Schael I. Serum IgA levels induced by rotavirus natural infection, but not following immunization with the RRV-TV vaccine (Rota-Shield), correlate with protection. J Med Virol. 2005;76:608-612
23. Schmitt H, Faber J, Lorenz I, Schmöle-Thoma B, Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-HiB vaccine. Vaccine. 2003;21:3653-3662
24. Matthews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2002 period linked birth/infant death data set. Natl Vital Stat Rep. 2004;53(10):1-29. Available at: www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_10.pdf